Literature DB >> 21158975

Interleukin-33: a novel mediator with a role in distinct disease pathologies.

M Kurowska-Stolarska1, A Hueber, B Stolarski, I B McInnes.   

Abstract

Interleukin-33 (IL-33) is a novel member of IL-1 cytokine family. It can act both as a nuclear factor and as a soluble mediator; however, the precise role of IL-33 within the nucleus is still not clear. As a cytokine, IL-33 is suggested to function as an alarmin that is released upon endothelial or epithelial cell damage. As such, IL-33 targets multiple cell types thereby alerting the immune system to endogenous trauma such as physical stress or infection. However, a dysregulated release of IL-33 has a potential to drive distinct pathologies. In this review, we discuss the contribution of IL-33 to the pathophysiology of asthma, arthritis, obesity and atherosclerosis as well as the potential of IL-33 for therapeutic intervention.
© 2010 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21158975     DOI: 10.1111/j.1365-2796.2010.02316.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  31 in total

1.  F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation.

Authors:  Jing Zhao; Jianxin Wei; Rachel K Mialki; Daniel F Mallampalli; Bill B Chen; Tiffany Coon; Chunbin Zou; Rama K Mallampalli; Yutong Zhao
Journal:  Nat Immunol       Date:  2012-06-03       Impact factor: 25.606

Review 2.  Molecular basis of applied biological therapeutics.

Authors:  U Andersson; K J Tracey
Journal:  J Intern Med       Date:  2011-01       Impact factor: 8.989

3.  Sublingual Immunotherapy Decreases Expression of Interleukin-33 in Children with Allergic Rhinitis.

Authors:  Yuanming Wang; Chuling Li; Yaxiong Xu; Deyu Xu; Gang Yang; Fang Liao; Xianglin Luo
Journal:  Indian J Pediatr       Date:  2018-05-23       Impact factor: 1.967

4.  Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Authors:  George P Christophi; Ross C Gruber; Michael Panos; Rebecca L Christophi; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2011-12-02       Impact factor: 3.969

5.  Identification and functional analysis of 9p24 amplified genes in human breast cancer.

Authors:  J Wu; S Liu; G Liu; A Dombkowski; J Abrams; R Martin-Trevino; M S Wicha; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

6.  IL-33 neutralization suppresses lupus disease in lupus-prone mice.

Authors:  Pin Li; Wei Lin; Xiangxiong Zheng
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

7.  Interleukin-33 in the human placenta.

Authors:  Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2012-11-23

Review 8.  Ubiquitin-proteasome signaling in lung injury.

Authors:  Natalia D Magnani; Laura A Dada; Jacob I Sznajder
Journal:  Transl Res       Date:  2018-04-23       Impact factor: 7.012

9.  IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo.

Authors:  Kimberly D Dyer; Caroline M Percopo; Helene F Rosenberg
Journal:  Immunol Lett       Date:  2012-12-11       Impact factor: 3.685

Review 10.  The immune pathogenesis of scleroderma: context is everything.

Authors:  Matthew B Greenblatt; Antonios O Aliprantis
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.